Expression of Human Kallikrein 1-related Peptidase 4 (KLK4) and MET Phosphorylation in Prostate Cancer Tissue: Immunohistochemical Analysis

Overview

Journal Hum Cell

Publisher Springer

Specialty Cell Biology

Date 2015 Apr 12

PMID 25862631

Citations 14

Authors

Shoichiro Mukai

Kenji Yorita

Koji Yamasaki

Takahiro Nagai

Toyoharu Kamibeppu

Satoru Sugie

Kazutaka Kida

Chie Onizuka

Hiromasa Tsukino

Toshio Kamimura

Toshiyuki Kamoto

Hiroaki Kataoka

Affiliations

Soon will be listed here.

Abstract

Resistance to or relapse after androgen deprivation therapy (ADT) remains a significant problem in patients with prostate cancer. Several studies have hypothesized that the overexpression of MET and the activating signaling axis in prostate cancer cells are associated with castration-resistant prostate cancer (CRPC). On the other hand, the expression of human kallikrein 1-related peptidase (KLK) 4, which activates plasma HGF activator zymogen, in prostate cancer patients with bone metastasis or advanced stage has also been reported. In this study, we analyzed the expression and phosphorylation of MET along with KLK4 by immunohistochemistry in 62 formalin-fixed paraffin-embedded sections of prostate cancer collected by needle biopsy at our hospital between 2006 and 2011. As a result, the phosphorylation of MET was observed in 56% (35 of 62 cases) and positively correlated with worsening PSA relapse rate in a group of ADT-treated patients (P = 0.0445), suggesting significant correlation with CRPC. Overexpression of KLK4 was observed in patients with high T stage (P = 0.0001) and high Gleason score (P = 0.0146), and the expression was correlated with the phosphorylation of MET (P = 0.0002). Pathologically, strong MET phosphorylation observed in specific architectures in prostate cancer, such as cribriform structures, ill-defined glands or solid patterns, suggested the significance of MET activation in promoting the architectural formation of prostate cancer. In addition, high positivity rate (80%) of phospho-MET staining at high-grade prostatic intraepithelial neoplasia (HGPIN) may indicate the importance of the activating signaling axis in the carcinogenesis of prostate cancer.

Citing Articles

Hypoxic Regulation of the KLK4 Gene in two Different Prostate Cancer Cells Treated with TGF- β.

Poyrazli F, Okuyan D, Kockar F, Turkoglu S Cell Biochem Biophys. 2024; 82(3):2797-2812.

PMID: 39026058 DOI: 10.1007/s12013-024-01396-5.

The roles of proteases in prostate cancer.

Koistinen H, Kovanen R, Hollenberg M, Dufour A, Radisky E, Stenman U IUBMB Life. 2023; 75(6):493-513.

PMID: 36598826 PMC: 10159896. DOI: 10.1002/iub.2700.

"Stromal cells in prostate cancer pathobiology: friends or foes?".

Pederzoli F, Raffo M, Pakula H, Ravera F, Nuzzo P, Loda M Br J Cancer. 2022; 128(6):930-939.

PMID: 36482187 PMC: 10006214. DOI: 10.1038/s41416-022-02085-x.

Investigating the Role of Obesity in Prostate Cancer and Identifying Biomarkers for Drug Discovery: Systems Biology and Deep Learning Approaches.

Yeh S, Chung Y, Chen B Molecules. 2022; 27(3).

PMID: 35164166 PMC: 8840188. DOI: 10.3390/molecules27030900.

LncRNA-PANDAR regulates the progression of thyroid carcinoma by targeting miR-637/KLK4.

Qing Y, Li Q, Zhao L, Shi P, Shan J, Zhang W J Cancer. 2021; 12(19):5879-5887.

PMID: 34476001 PMC: 8408101. DOI: 10.7150/jca.55181.

References

Knudsen B, Edlund M . Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res. 2004; 91:31-67. DOI: 10.1016/S0065-230X(04)91002-0. View

Gao J, Collard R, Bui L, Herington A, Nicol D, Clements J . Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate. 2007; 67(4):348-60. DOI: 10.1002/pros.20465. View

Kirchhofer D, Peek M, Lipari M, Billeci K, Fan B, Moran P . Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 2005; 579(9):1945-50. DOI: 10.1016/j.febslet.2005.01.085. View

Dong Y, Bui L, Odorico D, Tan O, Myers S, Samaratunga H . Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms. Endocr Relat Cancer. 2005; 12(4):875-89. DOI: 10.1677/erc.1.01062. View

Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H . Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2014; 44(4):388-96. DOI: 10.1093/jjco/hyu003. View

Schalken J, van Leenders G . Cellular and molecular biology of the prostate: stem cell biology. Urology. 2003; 62(5 Suppl 1):11-20. DOI: 10.1016/s0090-4295(03)00758-1. View

Dorn J, Bayani J, Yousef G, Yang F, Magdolen V, Kiechle M . Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies. Thromb Haemost. 2013; 110(3):408-22. DOI: 10.1160/TH13-03-0206. View

Maeda A, Nakashiro K, Hara S, Sasaki T, Miwa Y, Tanji N . Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells. Biochem Biophys Res Commun. 2006; 347(4):1158-65. DOI: 10.1016/j.bbrc.2006.07.040. View

van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J . Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate. 2002; 51(2):98-107. DOI: 10.1002/pros.10073. View

10.

Inoue T, Kataoka H, Goto K, Nagaike K, Igami K, Naka D . Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci. 2004; 95(10):803-8. PMC: 11158965. DOI: 10.1111/j.1349-7006.2004.tb02185.x. View

11.

Smith M, Sweeney C, Corn P, Rathkopf D, Smith D, Hussain M . Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol. 2014; 32(30):3391-9. PMC: 4383838. DOI: 10.1200/JCO.2013.54.5954. View

12.

Lee S, Dickson R, Lin C . Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem. 2000; 275(47):36720-5. DOI: 10.1074/jbc.M007802200. View

13.

Verras M, Lee J, Xue H, Li T, Wang Y, Sun Z . The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 2007; 67(3):967-75. DOI: 10.1158/0008-5472.CAN-06-3552. View

14.

Shimomura T, Kondo J, Ochiai M, Naka D, Miyazawa K, Morimoto Y . Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem. 1993; 268(30):22927-32. View

15.

Yasuda K, Nagakawa O, Akashi T, Fujiuchi Y, Koizumi K, Komiya A . Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. Prostate. 2008; 69(4):346-51. DOI: 10.1002/pros.20890. View

16.

Center M, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O . International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61(6):1079-92. DOI: 10.1016/j.eururo.2012.02.054. View

17.

Avgeris M, Stravodimos K, Scorilas A . Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance. Prostate. 2011; 71(16):1780-9. DOI: 10.1002/pros.21395. View

18.

Kataoka H, Kawaguchi M . Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo. FEBS J. 2010; 277(10):2230-7. DOI: 10.1111/j.1742-4658.2010.07640.x. View

19.

Kataoka H, Miyata S, Uchinokura S, Itoh H . Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev. 2003; 22(2-3):223-36. DOI: 10.1023/a:1023051500010. View

20.

Wozney J, Antonarakis E . Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev. 2014; 33(2-3):581-94. PMC: 4090293. DOI: 10.1007/s10555-013-9475-z. View